Indian Patent Office overturns Sovaldi ruling

The Indian Patent Office of New Delhi granted Gilead Sciences Inc. (NASDAQ:GILD) a patent covering active metabolites of HCV drug Sovaldi sofosbuvir, reversing an earlier ruling (see BioCentury Extra, Jan. 15, 2015).

In Monday's Harvoni sofosbuvir/ledipasvir for distribution in 91 developing countries (see BioCentury Extra, Sept. 15, 2014). ...